Title

Food and Drug Committee FDA Flash! - REMS May Mitigate Patient Risk, But Increase Risk to Drug Manufacturers

Announcement Description

​Check out our new FDA Flash! article, REMS May Mitigate Patient Risk, But Increase Risk to Drug Manufacturers:  Novo Nordisk Settles REMS-Related Claims for Over $58 Million, by Lynn C. Tyler, Partner, Barnes & Thornburg LLP (October 9, 2017).

Expires

 

Attachments

Created at 10/12/2017 9:19 AM by Shana Cyr
Last modified at 10/12/2017 9:19 AM by Shana Cyr